Skip to Main Content

Print | Bookmark | Font Size: + |

July 3, 2025

Correct Billing & Payment for CAR T-Cell & Other Immunotherapy Cases

Effective for inpatient (TOB 11X) claims with discharge dates on or after October 1, 2020:

  • MS-DRG 018 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies) assigns to cases that include procedures describing CAR T-cell therapies.
  • A payment adjustment applies to clinical trial or expanded access use immunotherapy cases where the CAR T-cell and other immunotherapy product isn’t purchased in the usual manner.
  • A payment adjustment doesn’t apply when the CAR T-cell therapy product is purchased in the usual manner, but the case involves a clinical trial of a different product.

Use the billing instructions below to ensure you receive the correct payment.

Clinical Trials

When the CAR T-cell and other immunotherapy product isn’t purchased in the usual manner, report:

  • Condition code 30
  • Value code D4 and the National Clinical Trial (NCT) number
  • Revenue code 0891 or 0892 with a covered token charge ($1.00 or less)
  • Diagnosis code Z00.6

The Pricer will apply the payment adjustment.

When the CAR T-cell and other immunotherapy product is purchased in the usual manner, but the case involves a clinical trial of a different product, report:

  • Condition code 30
  • Value code D4 and the NCT number
  • Revenue code 0891 or 0892 with covered charges (greater than $1.00)
  • Diagnosis code Z00.6
  • Billing Note NTE02 (837I electronic claim) or Remarks (Direct Data Entry (DDE) or paper claim): “Diff Prod Clin Trial”

Important: You must report “Diff Prod Clin Trial” verbatim; the Pricer won’t apply the payment adjustment.

Expanded Access

Report the following:

  • Condition code 90
  • Revenue code 0891 or 0892 with a covered token charge ($1.00 or less)
  • Billing Note NTE02 (837I electronic claim) or Remarks (DDE or paper claim): “Expand Acc Use”

The Pricer will apply the payment adjustment.

Resources

  • CR13926External PDF – Fiscal Intermediary Shared System (FISS) Changes to Automate the Application of Condition Code ZC for Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapy Cases Involving a Clinical Trial of a Different Product
  • MM12814External PDF – Inpatient & Long-Term Care Hospital Prospective Payment System: FY 2023 Changes
  • MM11879External PDF – Fiscal Year (FY) 2021 Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) PPS Changes
  • NCD 110.24: CAR T-Cell Therapy Billing Instructions

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved